HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunscreen Antiaging Claim Ban Challenged At "Feedback" Meeting

This article was originally published in The Rose Sheet

Executive Summary

Sunscreen labeling language should go beyond sunburn prevention use and state the products' protective effects against premature aging and skin damage, industry and medical representatives told FDA at an OTC "feedback" meeting in Rockville, Md July 22.

You may also be interested in...



FDA May Reconsider "SPF 30+" Sunscreen Labeling Requirement

FDA expressed willingness to reconsider the provision in the sunscreen final monograph that restricts products with sun protection factors over 30 to state only that they are SPF "30 plus."

"SPF 30 Plus" Term Required For High-Protection Sunscreens - FDA Final Reg

Sunscreens containing an SPF over 30 will be required to use one collective term, "SPF 30 plus" or "SPF 30+" on labeling under FDA's final sunscreen monograph published in the Federal Register May 21. Due to the projected considerable economic burden on sunscreen manufacturers to comply with the regulation, FDA is extending the proposed 12-month compliance deadline to 24 months (for other provisions, see chart, p. 18).

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel